Znanstveni rad - Prikaz slučaja
Risk Factors for Rivaroxaban-Related Bleeding Events - Possible Role of Pharmacogenetics: Case Series
Pharmacy, 11 (2023), 1; 29. https://doi.org/10.3390/pharmacy11010029


Citirajte ovaj rad

Šimičević, L., Slišković, A. M., Vrkić Kirhmajer, M., Ganoci, L., Holik, H., Palić, J. ... Božina, T. (2023). Risk Factors for Rivaroxaban-Related Bleeding Events - Possible Role of Pharmacogenetics: Case Series. Pharmacy, 11. (1). doi: 10.3390/pharmacy11010029

Šimičević, Livija, et al. "Risk Factors for Rivaroxaban-Related Bleeding Events - Possible Role of Pharmacogenetics: Case Series." Pharmacy, vol. 11, br. 1, 2023. https://doi.org/10.3390/pharmacy11010029

Šimičević, Livija, Ana Marija Slišković, Majda Vrkić Kirhmajer, Lana Ganoci, Hrvoje Holik, Jozefina Palić, Jure Samardžić i Tamara Božina. "Risk Factors for Rivaroxaban-Related Bleeding Events - Possible Role of Pharmacogenetics: Case Series." Pharmacy 11, br. 1 (2023). https://doi.org/10.3390/pharmacy11010029

Šimičević, L., et al. (2023) 'Risk Factors for Rivaroxaban-Related Bleeding Events - Possible Role of Pharmacogenetics: Case Series', Pharmacy, 11(1). doi: 10.3390/pharmacy11010029

Šimičević L, Slišković AM, Vrkić Kirhmajer M, Ganoci L, Holik H, Palić J, i sur.. Risk Factors for Rivaroxaban-Related Bleeding Events - Possible Role of Pharmacogenetics: Case Series. Pharmacy [Internet]. 05.02.2023. [pristupljeno 12.07.2024.];11(1). doi: 10.3390/pharmacy11010029

L. Šimičević, et al., "Risk Factors for Rivaroxaban-Related Bleeding Events - Possible Role of Pharmacogenetics: Case Series", Pharmacy, vol. 11, br. 1, Veljača 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:385266. [Citirano: 12.07.2024.]

Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.